scholarly journals The Role of Secondary Surgery in Recurrent Ovarian Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
D. Lorusso ◽  
M. Mancini ◽  
R. Di Rocco ◽  
R. Fontanelli ◽  
F. Raspagliesi
Keyword(s):  
Ovarian Cancer ◽  
Randomized Trials ◽  
Advanced Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Review Of Literature ◽  
Secondary Surgery ◽  
Primary Ovarian Cancer ◽  
Literature Evidence ◽  
Major Treatment

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

The role of anthracyclines in second-line therapy of ovarian cancer

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 178-184 ◽  
Author(s):  
J. B. Vermorken
Keyword(s):  
Ovarian Cancer ◽  
Randomized Trials ◽  
Single Agent ◽  
Advanced Ovarian Cancer ◽  
Pegylated Liposomal Doxorubicin ◽  
Second Line ◽  
Toxicity Profile ◽  
Platinum Sensitive ◽  
Platinum Based Chemotherapy

Anthracyclines (ANTs) have been in clinical practice since the 1960s and represent one of the most commonly used classes of anticancer drugs. In the 1990s, meta-analyses showed a favorable impact of doxorubicin (DOX/A) on the survival of patients with advanced ovarian cancer, when it was combined with cyclophosphamide and cisplatin (CAP) and compared to CP alone. With the acceptance of paclitaxel-carboplatin (TCb) as the new reference arm for first-line treatment, testing the addition of ANTs to TCb seems a logic next step. Trials presently testing this, make use of either epirubicin (EPI) or pegylated liposomal doxorubicin (PLD: Doxil®/Caelyx®). These are the two most favorable ANTs, based on data obtained with various ANTs in ovarian cancer failing platinum-based chemotherapy. EPI has not been evaluated in direct comparison with other antineoplastic agents. PLD has been compared with both paclitaxel and topotecan. No difference in efficacy parameters could be observed, but the toxicity profile of PLD scored favorably against those of the comparator in both trials, despite the fact that palmar-plantar erythrodysesthesia can be troublesome, and sometimes lead to treatment discontinuation. Data from four randomized trials evaluating the role of ANT combinations in patients with relapsed ovarian cancer suggest that the addition of EPI or DOX to paclitaxel does not lead to better outcomes in patients with platinum-refractory or resistant disease. In platinum-sensitive disease, any benefit of EPI-platinum or DOX-platinum combinations over platinum alone is uncertain. There are no randomized trials with PLD combinations in the second-line setting. It is concluded that both EPI and PLD can be recommended as a reasonable single-agent treatment option for relapsed patients, with a preference for PLD taking into account its more favorable toxicity profile.

ROLE OF ULTRASOUND IN THE DETECTION OF RECURRENT OVARIAN CANCER

2020 ◽  
Vol 6 (1) ◽  
pp. 23-31
Author(s):  
M. Alisherova ◽  
◽  
M. Ismailova
Keyword(s):  
Ovarian Cancer ◽  
Surgical Treatment ◽  
Reproductive System ◽  
Malignant Tumors ◽  
Recurrent Ovarian Cancer ◽  
Primary Diagnosis ◽  
Female Reproductive System

Currently, there are no standard approaches to monitoring patients with ovarian cancer (OC). While the role of ultrasound (US) has been identified in the primary diagnosis of OS, it is still controversial during the subsequent surgical treatment of OC. In world statistics, ovarian cancer is consistently among the four main localizations of malignant tumors of the female reproductive system, along with tumors of the breast, body and cervix.

The role of CT, PET-CT, and MRI in ovarian cancer

2021 ◽  
Vol 94 (1125) ◽  
pp. 20210117
Author(s):  
Maurits Peter Engbersen ◽  
Willemien Van Driel ◽  
Doenja Lambregts ◽  
Max Lahaye
Keyword(s):  
Ovarian Cancer ◽  
Essential Role ◽  
Advanced Ovarian Cancer ◽  
Emission Tomography ◽  
Current Position ◽  
Positron Emission ◽  
Pet Ct ◽  
New Treatment ◽  
Ct And Mri

New treatment developments in ovarian cancer have led to a renewed interest in staging advanced ovarian cancer. The treatment of females with ovarian cancer patients has a strong multidisciplinary character with an essential role for the radiologist. This review aims to provide an overview of the current position of CT, positron emission tomography-CT, and MRI in ovarian cancer and how imaging can be used to guide multidisciplinary team discussions.

scholarly journals Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

2019 ◽  
Vol 69 (1) ◽  
pp. 87-97
Author(s):  
Saima Sattar ◽  
Mobasher Ahmad ◽  
Hamid Saeed ◽  
Zikria Saleem ◽  
Zeeshan Danish ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Histological Grade ◽  
Progression Free Survival ◽  
Complete Response ◽  
Recurrent Ovarian Cancer ◽  
Figo Stage ◽  
Care Hospital ◽  
Pathological Characteristics ◽  
Literature Evidence

Abstract Despite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo-protocols, from a specialized cancer care hospital, Lahore, Pakistan, using convenient judgmental sampling. The study was conducted for a period of 6 months. Most of the patients were between 18 and 70 years of age, with IIIC FIGO stage and papillary serous histological grade. As per RECIST, improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm, substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms, respectively, yet with no significant differences in survival curves, PFS (p = 0.12) and OS (p = 0.22). Interestingly, the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, resp. As per the hazard model for survival, topotecan showed significant association with the therapy related events/deaths compared to other protocols. These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore.

Role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer

2012 ◽  
Vol 125 ◽  
pp. S107
Author(s):  
V. Kolev ◽  
E. Pereira ◽  
S. Roayaie ◽  
D. Labow ◽  
M. Schwartz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liver Resection ◽  
Recurrent Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document